You’re wrong. It’s too much to ask people biased by 35 years of misinformation, amyloid/placques as the cause for Alzheirmer’s, to do an about face in 2 hours. It is not decided yet.
We should have been finishing a proper trial by now...
I posted a timeline previously. After CTAD December 2022, a proper trial i could have commenced Summer 2023, recruited by summer 2024 and the last patient would be doing their week 72 visit this month. What a waste to have an incompetent CEO. He strung this out as long as he could to get/vest his options.
Whats a proper trial: 800-1000 patients 50:50 with placebo/30 mg, slow titration, S1R subgroup at top of primary endpoint hierarchy in the SAP. End points could be CDR-SB OR co-primary ADAS-Cog14 AND (ADCS-iADL OR ADCS-MCI-ADL) Of course there is no guarantee but clear success in a trial like, combined with partial success in the 2b/3 would lead to high chance of approval by both FDA and EMA.